Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 3, 2009, Pages 288-298

  De Luca, Giuseppe ^a   Michael Gibson, C ^b   Bellandi, Francesco ^c   Murphy, Sabina ^b   Maioli, Mauro ^c   Noc, Marko ^d   Zeymer, Uwe ^e   Dudek, Dariusz ^f   Arntz, Hans Richard ^g   Zorman, Simona ^d   Gabriel, H Mesquita ^h   Emre, Ayse ⁱ   Cutlip, Donald ^j   Rakowski, Tomasz ^f   Gyongyosi, Mariann ^k   Huber, Kurt ^l   van't Hof, Arnoud W J ^m  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Prato Hospital   (Italy)

^d UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^e KLINIKUM LUDWIGSHAFEN   (Germany)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h HOSPITAL DE SANTA MARIA   (Portugal)

ⁱ DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l WILHELMINEN HOSPITAL   (Austria)

^m HOSPITAL DE WEEZENLANDEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ANGIOPLASTY; ARTICLE; ARTIFICIAL EMBOLISM; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; HEART INFARCTION SIZE; HEART MUSCLE PERFUSION; HUMAN; META ANALYSIS; PATIENT SAFETY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; SURGICAL MORTALITY; SYSTEMATIC REVIEW;

ANGIOPLASTY; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 70349161228     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-008-0296-9     Document Type: Article

References (45)

1. Nallamothu BK, Bates ER, Herrin J, Wang Y, Bradley EH, Krumholz HM, NRMI Investigators (2005) Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States national registry of myocardial infarction (NRMI)-3/4 analysis. Circulation 111:761-767. doi: 10.1161/01.CIR.0000155258.44268.F8
2. De Luca G, Suryapranata H, Ottervanger JP, Antman EM (2004) Time-delay to treatment and mortality in primary angioplasty for acute myocardial infarction: Every minute delay counts. Circulation 109:1223-1225. doi: 10.1161/01.CIR.0000121424.76486.20
3. De Luca G, van't Hof AW, de Boer MJ, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, Suryapranata H (2004) Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J 25:1009-1013. doi: 10.1016/j.ehj.2004.03.021
4. Tarantini G, Cacciavillani L, Corbetti F, Ramondo A, Marra MP, Bacchiega E, Napodano M, Bilato C, Razzolini R, Iliceto S (2005) Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: A study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol 46:1229-1235. doi: 10.1016/j.jacc.2005.06.054
5. Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffin J, Mattos L, Lansky AJ, O'Neill WW, Grines CL (2001) Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: Analysis from the primary angioplasty in myocardial infarction trials. Circulation 104:636-641. doi: 10.1161/ hc3101.093701
6. De Luca G, Ernst N, Zijlstra F, van't Hof AW, Hoorntje JC, Dambrink JH, de Boer MJ, Suryapranata H (2004) Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 43:1363-1367. doi: 10.1016/ j.jacc.2003.11.042
7. De Luca G, Gibson MC, Bellandi F et al. (2008) Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation. An individual patients' data meta-analysis. Heart (Epub ahead of print, May 12)
8. The TIMI Study Group (1985) The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 312:932-936
9. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F (1998) Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 97:2302-2306
10. Henriques JP, Zijlstra F, Ottervanger JP, de Boer MJ, van't Hof AW, Hoorntje JC, Suryapranata H (2002) Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 23:1112-1117. doi: 10.1053/euhj.2001.3035
11. Demets DL (1987) Methods for combining randomized clinical trials: strengths and limitations. Stat Med 6:341-350. doi: 10.1002/ sim.4780060325
12. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 359:189-198. doi: 10.1016/ S0140-6736(02)07442-1
13. Bolognese L (2000) Effects of pre-treatment with abciximab on coronary artery patency and microcirculation in high risk patients with acute myocardial infarction elegible for primary angioplasty: Results of the Abciximab patients evaluation (APE) randomized pilot study. Circulation 10(Suppl A):150
14. van't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, Petronio S, Marcel Gosselink AT, Jap W, Hollak F, Hoorntje JC, Suryapranata H, Dambrink JH, Zijlstra F, On-TIME study group (2004) Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: Results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 25:837-846. doi: 10.1016/j.ehj.2004.04.003
15. Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, Seidl K, Schroder R, Schneider S, Senges J (2005) Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: Results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 26:1971-1977. doi: 10.1093/eurheartj/ehi293
16. Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, Giri S, Caputo RP (2003) Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 92:977-980. doi: 10.1016/ S0002-9149(03)00983-4
17. Zorman S, Zorman D, Noc M (2002) Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 90:533-536. doi: 10.1016/S0002-9149(02)02530-4
18. Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, Huston M, Schreiber D, DiBattiste PM, Yeung AC (2003) TIrofiban given in the emergency room before primary angioplasty. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 107:1497-1501. doi: 10.1161/01.CIR.0000056120.00513.7A
19. Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP (2007) Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol 49:1517-1524. doi: 10.1016/j.jacc.2006.12.036
20. Rakowski T, Zalewski J, Legutko J, Bartus S, Rzeszutko L, Dziewierz A, Sorysz D, Bryniarski L, Zmudka K, Kaluza GL, Dubiel JS, Dudek D (2007) Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: A randomized study. Am Heart J 153:360-365. doi: 10.1016/ j.ahj.2006.12.007
21. Arntz HR, Schroder J, Schwimmbeck P, Pels K, Witzenbicheler B, Schultheiss HP (2004) Is early prehospital administration of abciximab superior to periprocedural theapy in patients with STEMI and planned PCI? Early and late results from the randomized REOMOBILE Pilot study. J Am Coll Cardiol 43(Suppl A):1002
22. Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA (2006) Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: Results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv 68:218-224. doi: 10.1002/ccd.20798
23. Gyöngyösi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, Hödl R, Gaul G, Bonner G, Wojta J, Laggner A, Glogar D, Huber K (2004) ReoPro-BRIDGING Study group use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING study. Eur Heart J 25:2125-2133. doi: 10.1016/j.ehj.2004.09.018
24. Emre A, Ucer E, Yesilcimen K, Bilsel T, Oz D, Sayar N, Terzi S, Akbulut T, Ersek B (2006) Impact of early tirofiban on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting. Cardiology 106:264-269. doi: 10.1159/000093408
25. Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, Kazziha S, Rokos I, Shammas NW, Palabrica TM, Fish P, McCabe CH, Braunwald E, TIMI Study Group (2006) Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 152:668-675. doi: 10.1016/j.ahj.2006.06.003
26. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ, Effron MB, Barnathan ES, Topol EJ (2008) FINESSE Investigators facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358:2205-2217. doi: 10.1056/NEJMoa0706816
27. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators (2006) Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): Randomised trial. Lancet 367:569-578. doi: 10.1016/S0140-6736(06)68147-6
28. Eisenberg PR, Sobel BE, Jaffe AS (1992) Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 19:1065-1069
29. Dudek D, Siudak Z, Janzon M et al. (2007) Patients transferred for primary PCI display reduced mortality when treatment with abciximab was started early compared with abciximab given in the cathlab. Results from the EUROTRANSFER Registry. Eur Heart J 28(Abstract Supplement):384
30. Huber K, Aylward PE, van't Hof AWJ, et al. (2007) Glycoprotein IIb-IIIa inhibitors before primary percutaneous coronary intervention of ST-Elevation myocardial infarction improve perfusion and outcomes: insights from APEX-AMI. Circulation 116:II-673. (Abstract)
31. Van't Hof AW, Ten Berg J, Heestermans T et al (2008) Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomised controlled trial. Lancet 372:537-546. doi: 10.1016/S0140-6736(08)61235-0
32. Ishihara M, Kagawa E, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nakama Y, Maruhashi T, Ookawa K, Dai K, Aokage Y (2007) Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol 99:1674-1679. doi: 10.1016/j.amjcard.2007.01.044
33. Antoniucci D, Valenti R, Migliorini A, Parodi G, Moschi G, Memisha G, Santoro GM, Cerisano G (2004) Impact of insulin-requiring diabetes mellitus on effectiveness of reperfusion and outcome of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 93:1170-1172. doi: 10.1016/ j.amjcard.2004.01.050
34. Timmer JR, van der Horst IC, De Luca G, Ottervanger JP, Hoorntje JC, de Boer MJ, Suryapranata H, Dambrink JH, Gosselink M, Zijlstra F, van't Hof AW, Zwolle Myocardial Infarction Study Group. (2005) Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 95:1375-1377. doi: 10.1016/j.amjcard.2005.01.088
35. Timmer JR, Ottervanger JP, de Boer MJ, Dambrink JH, Hoorntje JC, Gosselink AT, Suryapranata H, Zijlstra F, van't Hof AW, Zwolle Myocardial Infarction Study Group (2005) Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol 45:999-1002. doi: 10.1016/j.jacc.2004.12.050
36. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, Stone GW (2007) Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol 100:206-210. doi: 10.1016/ j.amjcard.2007.02.080
37. Prasad A, Stone GW, Stuckey TD, Costantini CO, Zimetbaum PJ, McLaughlin M, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, Lansky AJ, Gersh BJ (2005) Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 45:508-514. doi: 10.1016/j.jacc.2004.10.054
38. Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, Paolisso G, Giugliano D (2000) Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 101:2247-2251
39. Booth G, Stalker TJ, Lefer AM, Scalia R (2001) Elevated ambient glucose induces acute inflammatory events in the microvasculature: Effects of insulin. Am J Physiol Endocrinol Metab 280:E848-E856
40. Hokama JY, Ritter LS, Davis-Gorman G, Cimetta AD, Copeland JG, McDonagh PF (2000) Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia. J Diabetes Compl 14:96-107. doi: 10.1016/S1056-8727(00)00068-4
41. Engler RL, Dahlgren MD, Morris DD, Peterson MA, Schmid-Schonbein GW (1986) Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol 251:H314-H323
42. Shechter M, Merz CN, Paul-Labrador MJ, Kaul S (2000) Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 35:300-307. doi: 10.1016/S0735-1097(99)00545-8
43. Coller BS (1999) Potential non-glycoprotein IIb/IIIa effects of abciximab. Am Heart J 138:S1-S5. doi: 10.1053/hj.1999.v138.99078
44. Schwarz M, Nordt T, Bode C, Peter K (2002) The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2). Thromb Res 107:121-128. doi: 10.1016/S0049-3848(02)00207-4
45. Angeja BG, Gunda M, Murphy SA et al (2002) TIMI myocardial perfusion grade and ST segment resolution: Association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 105:282-285. doi: 10.1161/hc0302.103588